Stacey Kuh
Analyst, TD Cowen & Co.
Replay available
Verrica Pharmaceuticals Inc. (VRCA) Q1 2025 Earnings Call
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) Q1 2025 earnings conference call, held 2025-05-13. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Kevin Gardner
Host, LifeSci Advisors
Kemp Dolliver
Analyst, Brookline Capital Markets
John Kirby
Interim Chief Financial Officer, Verica Pharmaceuticals
Serge Belanger
Analyst, Needham & Company
Jason Rieger
President and Chief Executive Officer, Verica Pharmaceuticals
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Verrica Pharmaceuticals Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:05.216 Good evening, ladies and gentlemen, and welcome to the Verica Pharmaceuticals First 00:00:05.216 -- 00:00:07.118 Quarter 2025 00:00:07.118 -- 00:00:12.143 Corporate Update Conference Call. At this time, all participants are in a 00:00:12.143 -- 00:00:17.868 listen-only mode. After the speaker's remarks, there will be a question-and-answer 00:00:17.868 -- 00:00:22.493 session. As a reminder, this conference is being recorded. 00:00:22.493 -- 00:00:28.448 I will now turn the call over to our host, Kevin Gardner of LifeSci Advisors. 00:00:28.448 -- 00:00:31.309 You may begin your conference. 00:00:31.611 -- 00:00:36.615 Thank you, operator. Hello, everyone, and welcome to Verica Pharmaceuticals' 00:00:36.615 -- 00:00:39.037 first quarter 2025 corporate 00:00:39.037 -- 00:00:44.582 update conference call. With me on the line this evening are Jason Rieger, President 00:00:44.582 -- 00:00:48.425 and Chief Executive Officer of Verica Pharmaceuticals, 00:00:48.425 -- 00:00:53.950 Noah Rosenberg, Chief Medical Officer, John Kirby, Interim Chief Financial 00:00:53.950 -- 00:00:59.060 Officer, and David Zawitz, Chief Operating Officer. 00:00:59.060 -- 00:01:04.107 As a reminder during today's call, management will make forward-looking statements. 00:01:04.107 -- 00:01:06.911 These statements may include expectations 00:01:06.911 -- 00:01:13.020 related to the commercialization of WICAN for the treatment of molluscum contagiosum 00:01:13.020 -- 00:01:18.408 in the United States, continued revenue growth, regulatory developments, 00:01:18.408 -- 00:01:23.435 the development of Verica's product candidates, the company's expected 00:01:23.435 -- 00:01:29.232 cash runway, and its ability to obtain funding for future operations. 00:01:29.232 -- 00:...